Advanced BioDesign

Advanced BioDesign is a clinical-stage biotechnology company that develops ALDH1 enzyme inhibitors to overcome tumor drug resistance in cancer patients. Its lead drug candidate, ABD-3001, is currently in clinical trials for acute myeloid leukemia, while its second-generation inhibitor targets solid tumors in combination with immunotherapy. The company also provides a predictive and prognostic test called ALDESCREEN to identify and stratify patients for treatment.